D. E. Shaw & Co., Inc. Ikena Oncology, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $122 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding IKNA
# of Institutions
55Shares Held
31.9MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.02MShares$7.48 Million1.36% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.09MShares$6.1 Million2.87% of portfolio
-
Bvf Inc San Francisco, CA4.01MShares$5.97 Million0.25% of portfolio
-
Bml Capital Management, LLC Zionsville, IN3.59MShares$5.34 Million3.65% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$5.27 Million0.16% of portfolio
About Ikena Oncology, Inc.
- Ticker IKNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,257,500
- Market Cap $54M
- Description
- Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...